	US 12,091,465 B2
	Composition for preventing or treating diseases caused by overexpression of chemokine CX₃CL1, containing death receptor inhibitor as active ingredient
Doo Hyun Chung, Seoul (KR); Eugene C. Yi, Seoul (KR); Dongjin Jeong, Seoul (KR); Min Jueng Kang, Seoul (KR); and Donghyun Kim, Seoul (KR)
Assigned to SEOUL NATIONAL UNIVERSITY R&DB FOUNDATION, Seoul (KR)
Appl. No. 16/637,357
Filed by Seoul National University R&DB Foundation, Seoul (KR)
PCT Filed Aug. 14, 2018, PCT No. PCT/KR2018/009351 § 371(c)(1), (2) Date Feb. 7, 2020, PCT Pub. No. WO2019/035646, PCT Pub. Date Feb. 21, 2019.
Claims priority of application No. 10-2017-0104381 (KR), filed on Aug. 17, 2017.
Prior Publication US 2023/0159650 A1, May 25, 2023
Int. Cl. C07K 14/705 (2006.01); A61P 19/02 (2006.01); C07K 14/71 (2006.01); C07K 16/28 (2006.01); C12N 15/113 (2010.01); G01N 33/68 (2006.01); A61K 39/00 (2006.01)

CPC C07K 16/2878 (2013.01) [A61P 19/02 (2018.01); C07K 14/70578 (2013.01); C07K 14/70596 (2013.01); C12N 15/113 (2013.01); C12N 15/1138 (2013.01); G01N 33/6872 (2013.01); A61K 2039/505 (2013.01); C12N 2310/11 (2013.01); C12N 2310/14 (2013.01); G01N 2333/70578 (2013.01)]

1 Claim

1. A method for treating a disease caused by overexpression of chemokine CX₃CL1 in a patient in need thereof, comprising administering a therapeutically effective amount of an inhibitor of expression or activity of DR5 to the patient, wherein the inhibitor of expression or activity of DR5 is a siRNA against DR5, and wherein the disease is arthritis.